Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 516-523

  Nahidi, Lily ^a   Leach, Steven T ^a   Sidler, Marc A ^b   Levin, Alon ^a   Lemberg, Daniel A ^b   Day, Andrew S ^a,c,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

children; Crohn's disease; exclusive enteral nutrition; osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; ENTERIC FEEDING; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; ENTERAL NUTRITION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; MALE; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 78651266930     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21361     Document Type: Article

References (34)

1. Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol. 2004; 138: 491-498.
2. Hyun E, Andrade-Gordon P, Steinhoff M, et al. Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut. 2008; 57: 1222-1229.
3. Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut. 2008; 57: 1386-1392.
4. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007; 42: 1321-1331.
5. Day AS, Whitten KE, Sidler MA, et al. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther. 2008; 27: 293-307.
6. Gramlich T, Petras RE,. Pathology of inflammatory bowel disease. Semin Pediatr Surg Inflamm Bowel Dis Child. 2007; 16: 154-163.
7. Chidlow Jr JH, Shukla D, Grisham MB, et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007; 293: 5-18.
8. Glickman JN,. Pathology of inflammatory bowel disease in children. Curr Diagn Pathol. 2005; 11: 117-124.
9. Sidler MA, Leach ST, Day AS,. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008; 14: 359-366.
10. Leach ST, Day AS,. S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease. Expert Rev Clin Immunol. 2006; 2: 471-480.
11. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005; 54: 479-487.
12. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008; 57: 684-694.
13. Shen F, Ruddy MJ, Plamondon P, et al. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. J Leukoc Biol. 2005; 77: 388-399.
14. Vidal K, Serrant P, Schlosser B, et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G836-844.
15. Kappelman MD, Bousvaros A,. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res. 2008; 52: 867-874.
16. Day AS, Whitten KE, De Jong NSH,. Nutrition and nutritional management of Crohn's disease in children and adolescents. Curr Nutr Food Sci. 2006; 2: 3-13.
17. De Jong NSH, Leach ST, Day AS,. Fecal A100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis. 2006; 12: 566-572.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19: 5-36.
19. Leach ST, Nahidi L, Tilakaratne S, et al. Development and assessment of a Modified Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr. 2010 [Epub ahead of print].
20. Yamamoto T, Saniabadi AR, Umegae S, et al. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006; 12: 719-726.
21. Bernstein CN, Leslie WD,. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003; 15: 857-864.
22. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996; 16: 144-150.
23. Rodriguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK,. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol. 2007; 13: 6156-6165.
24. Clowes JA, Riggs BL, Khosla S,. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005; 208: 207-227.
25. Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr. 2006; 148: 461-466.
26. Bernstein CN, Sargent M, Leslie WD,. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis. 2005; 11: 325-330.
27. Harpavat M, Greenspan SL, O'Brien C, et al. Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J Pediatr Gastroenterol Nutr. 2005; 40: 295-300.
28. Skinner A, Lerer T, Wyzga N, et al. S1225 Fecal osteoprotegerin: a marker for pediatric ulcerative colitis at diagnosis - a pilot study. Gastroenterology. 2008; 134: A205.
29. Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006; 21: 1609-1614.
30. Leach ST, Mitchell HM, Eng WR, et al. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther. 2008; 28: 724-733.
31. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther. 2000; 14: 281-289.
32. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006; 4: 744-753.
33. De Jong NSH, Leach ST, Day AS,. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig Dis Sci. 2007; 52: 2029-2036.
34. Whitten K, Leach ST, Bohane T, et al. Effect of exclusive enteral nutrition on bone metabolism in children with Crohn's disease. J Gastroenterol. 2010; 45: 399-405.